Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18931989 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18630828 | COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS | April 2024 | January 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18610930 | RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use | March 2024 | March 2025 | Allow | 12 | 2 | 1 | No | No |
| 18185478 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | March 2023 | February 2025 | Abandon | 23 | 0 | 0 | No | No |
| 17744634 | COMPOSITIONS FOR INTRATUMORAL ADMINISTRATION AND RELATED METHODS | May 2022 | June 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17310354 | ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENT | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17425529 | NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17367201 | NOVEL METHOD FOR MONITORING ENDOMETRIOSIS AND ASSOCIATED DISORDERS | July 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17359775 | POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF | June 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17416286 | EXPRESSION VECTORS FOR EUKARYOTIC EXPRESSION SYSTEMS | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17415164 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17057087 | TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY | June 2021 | June 2025 | Abandon | 55 | 2 | 1 | Yes | No |
| 17303890 | CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17298114 | OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPs | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17309140 | BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING | April 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17234455 | METHOD FOR PREVENTING OR TREATING CANCER USING SYT11 INHIBITOR | April 2021 | April 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17277663 | EXPRESSION VECTORS FOR EUKARYOTIC EXPRESSION SYSTEMS | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17277672 | QUANTITATIVE REGULATION OF A G PROTEIN SIGNALLING PATHWAY | March 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17273949 | SCREENING SYSTEM FOR HUMAN-TRANSFORMED CARTILAGE CELL LINE-BASED CARTILAGE DISEASE TREATMENT AGENTS | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17268592 | Methods of Managing Nucleic Acid Replication, Expression, and Cleavage Using CRISPR Associated Nucleases | February 2021 | May 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17174961 | IN SITU SPATIAL BARCODING | February 2021 | March 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17253863 | Nucleases For Genome Editing | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17103637 | SCREENING AND APPLICATION OF SGRNA FOR AHI1 GENE EDITING | November 2020 | April 2025 | Abandon | 53 | 2 | 0 | No | No |
| 16970003 | MODIFIED ADENOVIRUSES | August 2020 | January 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 16963476 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH UPREGULATED PERIOSTIN EXPRESSION OR PERIOSTIN SPLICE VARIANT SWITCHING | July 2020 | December 2024 | Allow | 52 | 2 | 0 | Yes | No |
| 16909499 | HELPER PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHOD | June 2020 | March 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 16711062 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | December 2019 | November 2024 | Abandon | 59 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MEYERING, SHABANA SHABBEER works in Art Unit 1635 and has examined 24 patent applications in our dataset. With an allowance rate of 37.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner MEYERING, SHABANA SHABBEER's allowance rate of 37.5% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MEYERING, SHABANA SHABBEER receive 1.29 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MEYERING, SHABANA SHABBEER is 45 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +90.0% benefit to allowance rate for applications examined by MEYERING, SHABANA SHABBEER. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.0% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 22.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.